A Phase 2 interventional study of Filgotinib and Placebo to match filgotinib in Noninfectious Uveitis, sponsored by Gilead Sciences. Terminated at 24 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-21.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.
Among the 139 studies in Uveitis with a site in United States, this one is the 30th largest by enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2017, is one of 28 in phase 2, and was the 107th registered.
300 studies on the registry are indexed under Uveitis; 32 are open to participants now.
Browse Uveitis studies →7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages up to 17
Quan Dong Nguyen · Sites in United States
Ages 18–70
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
Meyer Children's Hospital IRCCS · Sites in United States, Belgium, Greece and 2 more countries
Ages 1–16
The Cleveland Clinic · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 40 · Phase 3 31 · Phase 4 9
First in 1987; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 19 across the 100 interventional studies, 123 across the 36 observational. Of the 117 that completed or were terminated, 50 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 139 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 1 study filed under Uveitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518134Jaeb Center for Health ResearchA Study of Uveitis in Children <18 Years of Age | 2027-04-01 |
| NCT04704609The Cleveland ClinicImaging Quantification of Inflammation (IQI) | 2027-04-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Uveitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.
Key Inclusion Criteria:
Must have active uveitic disease at the Day 1/Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral equivalent:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
Drug: Filgotinib · Drug: Prednisone
Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
Drug: Placebo to match filgotinib · Drug: Prednisone
Tablet(s) administered orally
Also known as: GS-6034, GLPG0634
Tablet(s) administered orally
Tablet(s) administered orally
Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24
Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Week (Wk) 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in Anterior Chamber (AC) cell grade (Standardization of Uveitis Nomenclature \[SUN\] criteria)\[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in Vitreous Haze (VH) grade (National Eye Institute \[NEI\]/SUN criteria)\[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of best corrected visual acuity (BCVA) by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.
Time frame: Week 6 through Week 24
Time to Treatment Failure on or After Week 6
Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Wk 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in AC cell grade (SUN criteria) \[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in VH grade (NEI/SUN criteria) \[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of BCVA by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.
Time frame: Week 6 through Week 52
Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET)
Grading of VH was based on the publication from the NEI which has also been adapted by the SUN working group. VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), with higher scores indicating greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET
The number of AC cells observed within a 1 mm × 1 mm slit beam were recorded for each eye. The reported number was used to determine the grade according to the SUN criteria. AC cell grades range from 0 (0 cells in field) to 4+ (\>50 cells in field), with higher scores indicating more cells visible in the AC and greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Change in Logarithm of the Minimal Angle of Resolution (logMAR) Best Corrected Visual Acuity (BCVA) in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET
BCVA is the best possible vision that an eye can achieve with the set of glasses or contact lenses. A refraction test was performed to measure the appropriate lens strength to focus light on the retina. Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. In the ETDRS system, 15 letters is equal to a change in 3 lines of visual acuity. If the participant is unable to read letters on a testing chart, visual acuity is described as ranging from ability to count fingers, recognize hand movements, or light perception. The smaller BVCA score indicates greater severity of uveitis. A positive change from best state value obtained prior to Week 6 indicates improvement.
Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Log Change in Central Retinal Thickness in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET
Central retinal thickness is measured by optical coherence tomography (OCT). Central retinal thickness is defined as the thickness of the retina in the center of the foveal pit (1 mm subfield). The larger central retinal thickness value indicates greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
Time frame: Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks)
Time to Development of Macular Edema in At Least One Eye on or After Week 6
Time in weeks until the development of Macular edema or Week 52 or EOT or ET. Macular edema is determined by OCT and is defined as central retinal thickness ≥ 300 microns if using Cirrus machine, or ≥ 315 microns if using Spectralis machine.
Time frame: Week 6 through Week 52
Plasma Concentration of Filgotinib
Time frame: Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time
Plasma Concentration of Metabolite, GS-829845
Time frame: Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time
Participants were enrolled at study sites in the United States, the United Kingdom, Canada, Australia, Germany, Israel, and New Zealand. The first participant was screened on 26 July 2017. The last study visit occurred on 22 April 2021.
| Milestone | Filgotinib | Placebo |
|---|---|---|
| Started | 38 | 36 |
| Completed | 30 | 29 |
| Not completed | 8 | 7 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Investigator's discretion | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Pregnancy/partner pregnancy | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 0 |
Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Week (Wk) 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in Anterior Chamber (AC) cell grade (Standardization of Uveitis Nomenclature \[SUN\] criteria)\[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in Vitreous Haze (VH) grade (National Eye Institute \[NEI\]/SUN criteria)\[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of best corrected visual acuity (BCVA) by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.
| percentage of participants | Filgotinib | Placebo |
|---|---|---|
| Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24 | 37.5 (19.2 to 55.8) | 67.6 (50.5 to 84.8) |
Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Wk 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in AC cell grade (SUN criteria) \[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in VH grade (NEI/SUN criteria) \[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of BCVA by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.
| weeks | Filgotinib | Placebo |
|---|---|---|
| Time to Treatment Failure on or After Week 6 | NA (24.1 to NA) | 22.0 (12.1 to 47.0) |
Grading of VH was based on the publication from the NEI which has also been adapted by the SUN working group. VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), with higher scores indicating greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
| score | Filgotinib | Placebo |
|---|---|---|
| Left Eye: Best State Prior to Week 6 | 0.3 ± 0.40 | 0.2 ± 0.33 |
| Right Eye: Best State Prior to Week 6 | 0.3 ± 0.36 | 0.3 ± 0.45 |
| Left Eye: Change From Best State at Week 52/EOT/ET | 0.1 ± 0.79 | 0.3 ± 0.75 |
| Right Eye: Change From Best State at Week 52/EOT/ET | 0.1 ± 0.62 | 0.2 ± 0.66 |
The number of AC cells observed within a 1 mm × 1 mm slit beam were recorded for each eye. The reported number was used to determine the grade according to the SUN criteria. AC cell grades range from 0 (0 cells in field) to 4+ (\>50 cells in field), with higher scores indicating more cells visible in the AC and greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
| score | Filgotinib | Placebo |
|---|---|---|
| Left Eye: Best State Prior to Week 6 | 0.0 ± 0.09 | 0.1 ± 0.19 |
| Right Eye: Best State Prior to Week 6 | 0.0 ± 0.12 | 0.1 ± 0.25 |
| Left Eye: Change From Best State at Week 52/EOT/ET | 0.2 ± 0.59 | 0.6 ± 0.87 |
| Right Eye: Change From Best State at Week 52/EOT/ET | 0.2 ± 0.53 | 0.7 ± 1.05 |
BCVA is the best possible vision that an eye can achieve with the set of glasses or contact lenses. A refraction test was performed to measure the appropriate lens strength to focus light on the retina. Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. In the ETDRS system, 15 letters is equal to a change in 3 lines of visual acuity. If the participant is unable to read letters on a testing chart, visual acuity is described as ranging from ability to count fingers, recognize hand movements, or light perception. The smaller BVCA score indicates greater severity of uveitis. A positive change from best state value obtained prior to Week 6 indicates improvement.
| logMAR | Filgotinib | Placebo |
|---|---|---|
| Left Eye: Best State Prior to Week 6 | 0.09 ± 0.195 | 0.07 ± 0.209 |
| Right Eye: Best State Prior to Week 6 | 0.09 ± 0.193 | 0.12 ± 0.280 |
| Left Eye: Change From Best State at Week 52/EOT/ET | 0.03 ± 0.154 | 0.05 ± 0.112 |
| Right Eye: Change From Best State at Week 52/EOT/ET | -0.01 ± 0.116 | 0.07 ± 0.144 |
Central retinal thickness is measured by optical coherence tomography (OCT). Central retinal thickness is defined as the thickness of the retina in the center of the foveal pit (1 mm subfield). The larger central retinal thickness value indicates greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
| log microns | Filgotinib | Placebo |
|---|---|---|
| Left Eye: Best State Prior to Week 6 | 2.45 ± 0.059 | 2.46 ± 0.097 |
| Right Eye: Best State Prior to Week 6 | 2.47 ± 0.056 | 2.44 ± 0.104 |
| Left Eye: Change From Best State at Week 52/EOT/ET | 0.01 ± 0.062 | 0.04 ± 0.080 |
| Right Eye: Change From Best State at Week 52/EOT/ET | 0.01 ± 0.049 | 0.03 ± 0.055 |
Time in weeks until the development of Macular edema or Week 52 or EOT or ET. Macular edema is determined by OCT and is defined as central retinal thickness ≥ 300 microns if using Cirrus machine, or ≥ 315 microns if using Spectralis machine.
| weeks | Filgotinib | Placebo |
|---|---|---|
| Time to Development of Macular Edema in At Least One Eye on or After Week 6 | 7.8 (6.1 to NA) | 12.3 (6.1 to NA) |
| nanograms per millilitre (ng/ml) | Filgotinib |
|---|---|
| Day 1 Postdose | 748.5 ± 1043.84 |
| Week 4 Predose | 173.3 ± 364.46 |
| Week 6 Predose | 133.9 ± 306.18 |
| Week 12 Postdose | 1088.7 ± 856.57 |
| Week 24 Single Anytime | 397.5 ± 561.57 |
| Week 36 Single Anytime | 295.7 ± 420.25 |
| Week 52 Single Anytime | 195.2 ± 344.54 |
| Early Termination Single Anytime | 434.8 ± 478.72 |
| ng/ml | Filgotinib |
|---|---|
| Day 1 Postdose | 230.8 ± 317.98 |
| Week 4 Predose | 2085.6 ± 924.91 |
| Week 6 Predose | 2107.7 ± 749.28 |
| Week 12 Postdose | 3237.0 ± 1180.74 |
| Week 24 Single Anytime | 3478.1 ± 1137.63 |
| Week 36 Single Anytime | 2944.3 ± 1130.84 |
| Week 52 Single Anytime | 2510.7 ± 1732.59 |
| Early Termination Single Anytime | 2171.0 ± 1224.77 |
Collected over Adverse Events: First dose date up to 30 days after the last dose of study drug (maximum exposure up to 57 weeks); All-Cause Mortality: From randomization up to 57 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib | 0/38 (0%) | 5/37 (13.5%) | 28/37 (75.7%) |
| Placebo | 0/36 (0%) | 2/35 (5.7%) | 19/35 (54.3%) |
| Event | Filgotinib | Placebo |
|---|---|---|
| Retinal vasculitisEye disorders | 0/37 | 1/35 |
| Urinary tract infectionInfections and infestations | 0/37 | 1/35 |
| UveitisEye disorders | 1/37 | 0/35 |
| Inflammatory bowel diseaseGastrointestinal disorders | 1/37 | 0/35 |
| Covid-19Infections and infestations | 1/37 | 0/35 |
| Spinal stenosisMusculoskeletal and connective tissue disorders | 1/37 | 0/35 |
| EpilepsyNervous system disorders | 1/37 | 0/35 |
| Suicidal ideationPsychiatric disorders | 1/37 | 0/35 |
| Bladder prolapseRenal and urinary disorders | 1/37 | 0/35 |
| Event | Filgotinib | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 3/37 | 7/35 |
| Visual impairmentEye disorders | 5/37 | 1/35 |
| Dry eyeEye disorders | 2/37 | 4/35 |
| InsomniaPsychiatric disorders | 4/37 | 4/35 |
| Abdominal painGastrointestinal disorders | 4/37 | 0/35 |
| NauseaGastrointestinal disorders | 4/37 | 1/35 |
| Urinary tract infectionInfections and infestations | 4/37 | 3/35 |
| FatigueGeneral disorders | 3/37 | 3/35 |
| HypertensionVascular disorders | 1/37 | 3/35 |
| PhotopsiaEye disorders | 3/37 | 0/35 |
Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Mean | 48 ± 15.1 | 43 ± 15.7 | 46 ± 15.5 |
| Sex: Female, Male(Participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Female | 23 | 20 | 43 |
| Male | 14 | 15 | 29 |
| Race/Ethnicity, Customized(Participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 4 | 10 | 14 |
| Ethnicity — Not Hispanic or Latino | 32 | 25 | 57 |
| Ethnicity — Not Permitted | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| Race — Asian | 4 | 0 | 4 |
| Race — Black or African American | 2 | 8 | 10 |
| Race — Native Hawaiian or Pacific Islander | 1 | 0 | 1 |
| Race — White | 29 | 26 | 55 |
| Race — Other | 1 | 1 | 2 |
| Region of Enrollment(participants) | Filgotinib | Placebo | Total |
|---|---|---|---|
| United States | 29 | 31 | 60 |
| United Kingdom | 4 | 2 | 6 |
| Canada | 2 | 0 | 2 |
| Australia | 1 | 0 | 1 |
| Germany | 0 | 1 | 1 |
| Israel | 0 | 1 | 1 |
| New Zealand | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2017 to primary completion in Dec 2020, 41 months.
Results were first posted in Jan 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634